Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Cybin Inc (NY: CYBN )

0.3611 -0.0127 (-3.40%)
Streaming Delayed Price Updated: 10:26 AM EDT, May 10, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Cybin Inc

< Previous 1 2
...
10 11 12 13 14 15 16 17 Next >
Developments with Ketamine Psychotherapy Are Driving A Medical Revolution For Treating Mental Health Issues
Palm Beach, FL –October 28, 2021 – FinancialNewsMedia.com News Commentary – Psychedelic drugs such as psilocybin, LSD and MDMA have tremendous medical and commercial future potential… and for ketamine,... 
Via FinancialNewsMedia
Topics Death Law Enforcement
Exposures Death Legal
Cybin Announces Launch of EMBARK Psychedelic Facilitator Training Program
From Cybin Inc.
Via Business Wire
PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Announces FDA IND Authorization of Potentially Pivotal Study
Via Investor Brand Network
Exposures Product Safety
North America Continues Leading The Way In Psychedelic Wellness
Palm Beach, FL –October 26, 2021 – FinancialNewsMedia.com News Commentary – The global psychedelic drugs market remains at an early stage in its life cycle, with most companies currently developing... 
Via FinancialNewsMedia
Cybin Announces FDA Investigational New Drug Authorization of Cybin’s Sponsored Feasibility Study Using Kernel Flow Technology
From Cybin Inc.
Via Business Wire
Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Files Patent Application Amid ‘New Era’ of Psychedelic Medicine
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Announces Completion of 74 In-Vitro and In-Vivo Evaluations of Expanding Portfolio
Via Investor Brand Network
Cybin Announces Completion of 74 Pre-Clinical Psychedelic Molecule Studies
From Cybin Inc.
Via Business Wire
PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Files International Patent Application in Continued Expansion of IP Portfolio
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
Cybin Files an International Patent Application Covering Psychedelic Delivery Methods
From Cybin Inc.
Via Business Wire
U.S. Is Dominating Psychedelic Drugs Market Due To Growing Acceptance For Treating Depression & Rise In Product Approvals
Palm Beach, FL –October 12, 2021 – FinancialNewsMedia.com News Commentary – After being relegated to the margins of sincere scientific examination for about the last several decades, growing... 
Via FinancialNewsMedia
PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Poised Amid New Research Surrounding Psilocybin
Via Investor Brand Network
Strong Pipeline of Drugs for Treatment Of Psychotic Disorders Anticipated To Drive The Market Through 2028
Palm Beach, FL –October 11, 2021 – FinancialNewsMedia.com News Commentary – There is a high demand for more advanced products for the treatment and maintenance of severe mental disorders. Thus,... 
Via FinancialNewsMedia
Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Announces New Executives, Internal Promotions
Via Investor Brand Network
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Announces Achievement of Adelia Milestones
Via Investor Brand Network
Cybin Announces Additional Adelia Milestone Achievements
From Cybin Inc.
Via Business Wire
PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Appoints New Executives, Promotes Team Members
Via Investor Brand Network
InvestorNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Appoints New Executives, Promotes Team Members
Via Investor Brand Network
Cybin Announces Appointment of Dr. Amir Inamdar as Chief Medical Officer for European Operations and Dr. Geoff Varty as the Head of Research and Development
From Cybin Inc.
Via Business Wire
NetworkNewsAudio – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Bringing Therapeutic Options to Diseases with Unmet Needs
Via Investor Brand Network
Topics Cannabis
Exposures Cannabis
Psychedelics Renaissance Underway as Paradigm Shifting Cure for Depression Potentially Discovered
Via FinancialNewsMedia
Topics Law Enforcement
Exposures Legal
Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Leading Out in Mental Health Treatment Innovation
Via Investor Brand Network
Exposures COVID-19
InvestorNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) CEO to Present in Two Upcoming Investor Conferences
Via Investor Brand Network
Investors Turning to Psychedelic Market as Renaissance Continues into New Wave of Diseases
Via Investor Brand Network
Topics Cannabis
Exposures Cannabis
Cybin to Present at Upcoming Cantor and Benzinga Investor Conferences
From Cybin Inc.
Via Business Wire
PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Garners Attention as ‘Emerging Leader in the Psychedelic Therapeutics Space’
Via Investor Brand Network
$10 Billion Sackler Opioid Settlement Closes Chapter, Psychedelic Chapter Begins
Via FinancialNewsMedia
Cybin to Present at the H.C. Wainwright 23rd Annual Global Investment Conference on September 13th
From Cybin Inc.
Via Business Wire
Cybin Announces Additional Adelia Milestone Achievements
From Cybin Inc.
Via Business Wire
Cybin Files Two Additional International Patent Applications in Support of the Company’s Research Phase Programs
From Cybin Inc.
Via Business Wire
< Previous 1 2
...
10 11 12 13 14 15 16 17 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.